In another phase I study, patients with HER2-positive progressed breast cancer who had previously received T-DM1 therapy were examined in a T-Dxd trial at fourteen centers, including eight in the USA and six in Japan [51]. The gene discussed is ERBB2; the disease is breast cancer.